Black Diamond Therapeutics (BDTX) grants 200K stock options to SVP

Rhea-AI Filing Summary

Black Diamond Therapeutics, Inc. reports an option grant to senior management. Officer Erika Jones, who serves as Senior Vice President, Finance and Corporate Controller, was granted a stock option to purchase 200,000 shares of common stock at an exercise price of $2.57 per share on January 21, 2026.

According to the vesting terms, 25% of the shares subject to this option will vest and become exercisable on January 21, 2027. The remaining 75% will vest in 36 equal monthly installments after that date, contingent on her continued service with the company. Following this grant, she holds 200,000 derivative securities (stock options) directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Erika

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.57	01/21/2026		A		200,000		(1)	01/20/2036	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Officer Title: Senior Vice President, Finance and Corporate Controller

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Black Diamond Therapeutics (BDTX) disclose for Erika Jones?

The company disclosed that officer Erika Jones received a grant of 200,000 stock options on January 21, 2026, giving her the right to buy common shares at a fixed exercise price.

What is the exercise price of Erika Jones’s new stock options at Black Diamond Therapeutics (BDTX)?

The stock option granted to Erika Jones has an exercise price of $2.57 per share for the underlying Black Diamond Therapeutics common stock.

How do the 200,000 stock options granted to Erika Jones at BDTX vest?

For this grant, 25% of the option shares vest and become exercisable on January 21, 2027, and the remaining shares vest in 36 equal monthly installments thereafter, subject to her continued service.

What is Erika Jones’s role at Black Diamond Therapeutics (BDTX) in this Form 4 filing?

In the filing, Erika Jones is identified as an officer of Black Diamond Therapeutics, serving as Senior Vice President, Finance and Corporate Controller.

How many derivative securities does Erika Jones beneficially own after this reported transaction at BDTX?

After the reported grant, Erika Jones beneficially owns 200,000 derivative securities (stock options) directly, as shown in the Form 4.

Are Erika Jones’s new stock options at Black Diamond Therapeutics (BDTX) held directly or indirectly?

The Form 4 indicates that the 200,000 stock options are held directly by Erika Jones, with no separate entity listed for indirect ownership.